

**SPRINT<sup>®</sup>**  
PNS SYSTEM

Sustained Pain Relief  
Starts Here<sup>™</sup>

**BREAKTHROUGH  
NEUROMODULATION  
TREATMENT**



# SPRINT<sup>®</sup>

PNS SYSTEM

## First-Line PNS<sup>™</sup>

The **SPRINT<sup>®</sup> PNS System**, by SPR<sup>®</sup> Therapeutics, marks an innovative shift in the treatment of pain. Our breakthrough PNS treatment is uniquely designed to recondition the central nervous system to provide significant and sustained relief from chronic pain.

- Short-term, 60-day treatment
- No permanent implant
- Minimally-invasive and drug-free

### Clinically proven.

The SPRINT PNS System is the most rigorously researched PNS System.<sup>8</sup> It has been studied extensively for low back pain, shoulder pain, post-amputation pain, and chronic and acute post-operative pain, and is cleared for use up to 60 days.\*

Over 70% of patients reported  
significant & sustained pain relief.\*




### Excellent safety profile.

- Most common adverse events are skin irritation and erythema
- Low risk of infection
- For more information visit [SprintPNS.com](https://SprintPNS.com)

\* Ref: 2,3,12-14,16-21

## Rethink Your Pain Strategy<sup>™</sup>


The SPRINT PNS System is a patient-preferred, low risk alternative to more invasive treatments such as ablation, permanent implants or surgery. Our breakthrough First-Line PNS treatment is proven to provide significant and sustained pain relief when prior treatments such as opioids or injections have failed.



### Patient-preferred.


Our system was recently ranked by patients as the most desirable treatment for chronic pain when compared to radiofrequency ablation and permanently implanted neuromodulation systems.<sup>10</sup>

#### Patient Preference



### Low risk. High reward.

In a comparison to other treatment options, physicians found the SPRINT PNS System to provide highly effective pain relief without a permanent implant, nerve damage or the risk of addiction.<sup>11</sup>




SPR Therapeutics, Inc, manufacturer of the SPRINT PNS System, has been awarded more than \$30 million in grants and contracts by the National Institutes of Health and the Department of Defense.



## Designed to Outsmart Pain™

The SPRINT PNS System is uniquely designed to selectively and robustly stimulate targeted peripheral nerve fibers for up to 60 days, modulating central plasticity to enable significant and sustained pain relief.




### Highly targeted:

Focuses stimulation on targeted nerve fibers to maximize therapeutic benefit and modulate central plasticity. See how it works at [SprintPNS.com](http://SprintPNS.com).



### Remote stimulation:

Our patented approach is designed to enable comfortable yet robust activation of nerve fibers to promote central plasticity while avoiding activation of non-target pain fibers.



*"A 60-day percutaneous treatment that delivers long-term relief without a permanent implant...this is a game changer."*

— **Peter Staats** MD, MBA, DABA, ABIPP, FIPP



## Patient-friendly technology.

The SPRINT PNS System is a minimally-invasive treatment option that helps patients get back to life. The MicroLead™ is implanted and then removed after treatment of up to 60 days. Patients can easily adjust the level of stimulation during treatment to comfortably provide pain relief.

### PULSE GENERATOR

Worn on the skin to deliver gentle pulses to the nerve. Powered by a rechargeable battery.

### MICROLEAD

Coiled 300 micron lead is designed to allow fibrotic ingrowth to reduce migration and infection risk.<sup>13</sup>



MICROLEAD

TISSUE  
INGROWTH

### ONEPASS INTRODUCER™

Single-stick percutaneous targeting for implanting the MicroLead. No incision, tunneling or stitches required.

### HAND-HELD REMOTE

User-friendly design allows patients to easily adjust stimulation levels.

## REFERENCES:

1. Deer TR, Eldabe S, Falowski SM, Huntoon MA, Staats PS, Cassar IR, Crosby ND, Boggs JW. *Peripherally Induced Reconditioning of the Central Nervous System: A Proposed Mechanistic Theory for Sustained Relief of Chronic Pain with Percutaneous Peripheral Nerve Stimulation*, Journal of Pain Research, Mar 2021;14 1-16
2. Gilmore CA, Desai MJ, Hopkins TJ, Li S, DePalma MJ, Deer TR, Grace W, Burgher AH, Sayal PK, Amirdelfan K, Cohen SP, McGee MJ, Boggs JW. Treatment of chronic axial back pain with 60-day percutaneous medial branch PNS: Primary endpoint results from a prospective, multicenter study. Pain Practice. 2021 Nov;21(8):877-89.
3. Deer TR, Gilmore CA, Desai MJ, Li SC, DePalma MJ, Hopkins TJ, Burgher AH, Spinner DA, Cohen SP, McGee MJ, Boggs JW. *Percutaneous Peripheral Nerve Stimulation of the Medial Branch Nerves for the Treatment of Chronic Axial Back Pain in Patients After Radiofrequency Ablation*, Pain Medicine, 2021; pnaa432, <https://doi.org/10.1093/pm/pnaa432>
4. Naidu R, Li S, Desai MJ, Sheth S, Crosby ND, Boggs JW. 60-Day PNS Treatment May Improve Identification of Delayed Responders and Non-Responders. American Society of Regional Anesthesia and Pain Medicine. San Francisco, CA, November 2021. President's Choice Award Winner.
5. Pingree MJ, Hurdle MFB, Spinner DA, Valimahomed A, Crosby ND, Boggs JW. Real World Evidence of Sustained Improvements Following Percutaneous PNS: A Retrospective Follow-Up Survey of 354 Patients. American Society of Regional Anesthesia and Pain Medicine. San Francisco, CA, November 2021. President's Choice Award Winner.
6. Ilfeld BM, Plunkett A, Vijjeswarapu AM, Hackworth R, Dhanjal S, Turan A, Cohen SP, Eisenach JC, Griffith S, Hanling S, Sessler DI. *Percutaneous Peripheral Nerve Stimulation (Neuromodulation) for Postoperative Pain: A Randomized, Sham-controlled Pilot Study*. Anesthesiology. 2021 Jul;135(1):95-110.
7. Ilfeld BM, Plunkett A, Vijjeswarapu AM, Hackworth R, Dhanjal S, Turan A, Cohen SP, Eisenach JC, Griffith S, Hanling S, Sessler DI. *Percutaneous Neuromodulation of the Brachial Plexus and Sciatic Nerve for the Treatment of Acute Pain Following Surgery: Secondary Outcomes From a Multicenter, Randomized, Controlled Pilot Study*. Neuromodulation: Technology at the Neural Interface. 2021 Aug 3.
8. Clinicaltrials.gov searches, updated 5.28.2021.
9. Gulati A, Desai MJ, Rosenow JM, Cohen SP, Crosby ND, Boggs JW. *Sustained Pain Relief Following 60-Day Percutaneous PNS in Majority of Patients: Review of Clinical Evidence*. Presented at the North American Neuromodulation Society, 2021 Jan 15-16.
10. Staats P, Deer T, Ottestad E, Erdek M, Spinner D, Gulati A. Understanding the role of patient preference in the treatment algorithm for chronic low back pain: results from a survey-based study. Pain management. 2021 Aug.
11. Physician Survey Data from PNS Leadership Forum, Scottsdale, AZ, December 2019. Data on file SPR Therapeutics.
12. Gilmore CA, Ilfeld BM, Rosenow JM et al. *Percutaneous 60-day Peripheral nerve stimulation implant provides sustained relief of chronic pain following amputation: 12-month follow-up of a randomized, double-blind, placebo-controlled trial*. Regional Anesthesia Pain Medicine 45. 2019 Nov 17; 44-51.
13. Gilmore CA, Kapural L, McGee MJ, Boggs JW. *Percutaneous Peripheral Nerve Stimulation for Chronic Low Back Pain: Prospective Case Series with 1 Year of Sustained Relief Following Short-Term Implant*. Pain Pract. 2019 Nov 6. doi: 10.1111/papr.12856.
14. Wilson RD, Bennett ME, Nguyen VQC et al. *Fully Implantable Peripheral Nerve Stimulation for Hemiplegic Shoulder Pain: A Multi-Site Case Series With Two-Year Follow-Up*. Neuromodulation 21. 2018 April 21;290-295.
15. Ilfeld BM, et al. *Infection Rates of Electrical Leads Used for Percutaneous Neurostimulation of the Peripheral Nervous System*. Pain Pract. (2016 Nov 11).
16. Rauck RL, Cohen SP, Gilmore CA et al. *Treatment of post-amputation pain with peripheral nerve stimulation*. Neuromodulation 17. 2014 Feb;188-197.
17. Wilson RD, Harris MA, Gunzler DD, Bennett ME, Chae J. *Percutaneous peripheral nerve stimulation for chronic pain in subacromial impingement syndrome: a case series*. Neuromodulation 17. 2014 Feb 11;771-776; discussion 776.
18. Wilson RD, Gunzler DD, Bennett ME, Chae J. *Peripheral nerve stimulation compared with usual care for pain relief of hemiplegic shoulder pain: a randomized controlled trial*. Am J Phys Med Rehabil 93. 2014 Jan;17-28.
19. Chae J, Wilson RD, Bennett ME, Lechman TE, Stager KW. *Single-lead percutaneous peripheral nerve stimulation for the treatment of hemiplegic shoulder pain: a case series*. Pain Pract 13. 2013 Aug 15;59-67.
20. Chae J, Yu DT, Walker ME, et al. *Intramuscular Electrical Stimulation for Hemiplegic Shoulder Pain*. American Journal of Physical Medicine & Rehabilitation 84. 2005 Nov;832-842.
21. Yu DT, Chae J, Walker ME, Fang ZP. *Percutaneous intramuscular neuromuscular electric stimulation for the treatment of shoulder subluxation and pain in patients with chronic hemiplegia: a pilot study*. Arch Phys Med Rehabil 82. 2001 Jan;20-25

The SPRINT PNS System is indicated for up to 60 days for: (i) Symptomatic relief of chronic, intractable pain, post-surgical and post-traumatic acute pain; (ii) Symptomatic relief of post-traumatic pain; and (iii) Symptomatic relief of post-operative pain. The SPRINT PNS System is not intended to treat pain in the region innervated by the cranial and facial nerves.

Physicians should use their best judgment when deciding when to use the SPRINT PNS System. For more information see the SPRINT PNS System IFU.

Most common adverse events are skin irritation and erythema. Results may vary. Rx only.

# Ready to champion a new protocol of care?

Learn more at [SprintPNS.com](https://SprintPNS.com) or contact us at 844.378.9108

**SPRINT**<sup>®</sup>  
PNS SYSTEM

First-Line PNS<sup>™</sup>

The SPRINT<sup>®</sup> PNS System, MicroLead<sup>™</sup>, OnePass Introducer<sup>™</sup>, Rethink Your Pain Strategy<sup>™</sup>, Outsmart Pain<sup>™</sup>, Sustained Pain Relief Starts Here<sup>™</sup> and SPR<sup>®</sup> are registered or common law trademarks of SPR Therapeutics, Inc.

© SPR THERAPEUTICS, INC 2021. MKT-000073(03)

